ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Tranquis Therapeutics has raised $30 million in series A funding to develop small-molecule therapies for neurodegenerative diseases. The San Mateo, California–based start-up aims to make compounds to boost metabolic pathways that are diminished in myeloid immune cells in people with neurodegenerative diseases. The strategy is based on the research of Stanford University immunologist Edgar Engleman. The firm’s initial programs will be for amyotrophic lateral sclerosis and frontotemporal dementia.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter